| Patent Number |
Title Of Patent |
Date Issued |
| 7553816 |
p-amidobenzylethers in drug delivery agents |
June 30, 2009 |
| Compounds of the formulas LA.sub.n-Z-X--W.sub.wD and BZ-X--W.sub.wD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-imm |
| 7498298 |
Monomethylvaline compounds capable of conjugation to ligands |
March 3, 2009 |
| Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. |
| 7423116 |
Pentapeptide compounds and uses related thereto |
September 9, 2008 |
| Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reactio |
| 7256257 |
Pentapeptide compounds and uses related thereto |
August 14, 2007 |
| Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reacti |
| 7098308 |
Pentapeptide compounds and uses related thereto |
August 29, 2006 |
| Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reacti |
| 7091186 |
p-Amidobenzylethers in drug delivery agents |
August 15, 2006 |
| Compounds of the formulae LA.sub.n-Z-X--W.sub.wD and BZ-X--W.sub.wD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide residue; X is an aminobenzyl ether self-immolative spacer group; W is an optional second |
| 6884869 |
Pentapeptide compounds and uses related thereto |
April 26, 2005 |
| Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reacti |
| 6132722 |
Recombinant antibody-enzyme fusion proteins |
October 17, 2000 |
| The invention is related to recombinantly produced fusion polypeptides comprising antibody V.sub.H and V.sub.L sequences operatively linked to a .beta.-lactamase for use in the delivery of cytotoxic drugs to tumor cells. |
| 5773435 |
Prodrugs for .beta.-lactamase and uses thereof |
June 30, 1998 |
| The instant invention relates to a novel method for the delivery of antitumor drugs to tumor cells by the administration of a tumor-selective antibody-.beta.-lactamase conjugate that binds to tumor cells, and the additional administration of a cephalosporin prodrug that is converted at |
| 5545548 |
Thermally stable cytosine deaminase from saccharomyces |
August 13, 1996 |
| Thermally stable cytosine deaminase (CDase), and the gene coding therefor, is disclosed as well as methods of isolating, purifying, and recombinantly producing the same. The thermally stable CDase can be isolated from Saccharomyces cerevisiae. The yeast isolated enzyme has a molecular we |
| 5338678 |
Expression of DNA sequences encoding a thermally stable cytosine deaminase from saccharomyces |
August 16, 1994 |
| Thermally stable cytosine deaminase (CDase), and the gene coding therefor, is disclosed as well as methods of isolating, purifying, and recombinantly producing the same. The thermally stable CDase can be isolated from Saccharomyces cerevisiae. The yeast isolated enzyme has a molecular we |
| 5041424 |
Epipodophyllotoxin glucoside 4'-phosphate derivatives |
August 20, 1991 |
| Phosphate derivatives of 4'-demethylepipodophyllotoxin glucosides are novel antitumor agents and the salts thereof offer the pharmaceutical advantage of high water solubility. |
| 4975278 |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to |
December 4, 1990 |
| This invention relates to a novel method for the delivery of cytotoxic drugs to tumor cells by the administration of a tumor-specific antibody-enzyme conjugate that binds to the tumor cells, and the additional administration of a prodrug that is converted at the tumor site, in the pr |
| 4952394 |
Drug-monoclonal antibody conjugates |
August 28, 1990 |
| There is disclosed a drug-monoclonal antibody conjugate wherein the antibody is linked to a antitumor drug using disulfide benzyl carbamate or carbonate as the linker. Also disclosed is a method of delivering an active antitumor drug to the site of tumor cells in a mammal by administ |
| 4904768 |
Epipodophyllotoxin glucoside 4'-phosphate derivatives |
February 27, 1990 |
| Phosphate derivatives of 4'-demethylepipodophyllotoxin glucosides are novel antitumor agents and the salts thereof offer the pharmaceutical advantage of high water solubility. |
| 4874779 |
Mitomycin phosphate derivatives |
October 17, 1989 |
| Disclosed herein are N.sup.7 -alkylphosphate derivatives of mitomycin C and porfiromycin showing antitumor activity against transplanted human tumor and reduced toxicity relative to the parent N.sup.7 -alkanol mitomycin compounds. |
